The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions
- PMID: 9247128
- DOI: 10.1016/s0014-5793(97)00412-2
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions
Abstract
Ligand-induced activation of receptor tyrosine kinases (RTK) results in the initiation of diverse cellular pathways, including proliferation, differentiation and cell migration. The ErbB family of RTKs represents a model for signal diversification through the formation of homo- and heterodimeric receptor complexes. Each dimeric receptor complex will initiate a distinct signaling pathway by recruiting a different set of Src homology 2- (SH2-) containing effector proteins. Further complexity is added due to the existence of an oncogenic receptor that enhances and stabilizes dimerization but has no ligand (ErbB-2), and a receptor that can recruit novel SH-2-containing proteins, but is itself devoid of kinase activity (ErbB-3). The resulting signaling network has important implications for embryonic development and malignant transformation.
Similar articles
-
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.Mol Cell Biol. 1999 Oct;19(10):6845-57. doi: 10.1128/MCB.19.10.6845. Mol Cell Biol. 1999. PMID: 10490623 Free PMC article.
-
Bivalence of EGF-like ligands drives the ErbB signaling network.EMBO J. 1997 Aug 15;16(16):4938-50. doi: 10.1093/emboj/16.16.4938. EMBO J. 1997. PMID: 9305636 Free PMC article.
-
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.Oncogene. 1998 Mar 12;16(10):1249-58. doi: 10.1038/sj.onc.1201642. Oncogene. 1998. PMID: 9546426
-
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):97-107. doi: 10.1023/a:1026343528967. J Mammary Gland Biol Neoplasia. 1997. PMID: 10882296 Review.
-
Signal transduction and oncogenesis by ErbB/HER receptors.Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13. doi: 10.1016/j.ijrobp.2003.06.002. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967450 Review.
Cited by
-
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.Front Oncol. 2023 Nov 29;13:1258365. doi: 10.3389/fonc.2023.1258365. eCollection 2023. Front Oncol. 2023. PMID: 38094609 Free PMC article.
-
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain.Mol Cell Biol. 2000 Oct;20(20):7735-50. doi: 10.1128/MCB.20.20.7735-7750.2000. Mol Cell Biol. 2000. PMID: 11003669 Free PMC article.
-
Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.Mol Cell Biol. 2002 Sep;22(18):6553-63. doi: 10.1128/MCB.22.18.6553-6563.2002. Mol Cell Biol. 2002. PMID: 12192053 Free PMC article.
-
An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations.Methods Enzymol. 2022;667:633-662. doi: 10.1016/bs.mie.2022.03.049. Epub 2022 Apr 20. Methods Enzymol. 2022. PMID: 35525557 Free PMC article.
-
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.Nat Rev Cancer. 2010 Sep;10(9):618-29. doi: 10.1038/nrc2900. Epub 2010 Aug 19. Nat Rev Cancer. 2010. PMID: 20720570 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
